Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli

Patent metadata

Field	Value
Publication number	US-11583565-B2
Application number	US-202016840334-A
Country	US
Kind code	B2
Filing date	Apr 4, 2020
Priority date	Apr 4, 2020
Publication date	Feb 21, 2023
Grant date	Feb 21, 2023

Abstract

A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.

First claim

What is claimed is:

1. A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli comprising:
a Myoviridae bacteriophage Esc-COP-15 having an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence as set forth in SEQ ID NO: 1; and
a pharmaceutically acceptable carrier,
wherein the Myoviridae bacteriophage Esc-COP-15 has a latent period of 20-70 minutes and a burst size of 80-200 plaque-forming units (PFU)/infected cell and is deposited in the Korean Collection for Type Cultures (KCTC) under accession number KCTC 14027BP; and
wherein the Myoviridae bacteriophage Esc-COP-15 has a concentration of 1×10 4 pfu/ml to 1×10 15 pfu/ml or 1×10 4 pfu/g to 1×10 15 pfu/g.

2. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil.

3. The composition of claim 1 further comprising:
one or more selected from the group consisting of a lubricant, a wetting agent, a sweetener, a flavor, an emulsifier, a suspending agent, and a preservative.

4. The composition of claim 1 , wherein the pathogenic Escherichia coli is enterohemorrhagic Escherichia coli , enterotoxigenic Escherichia coli , enteroinvasive Escherichia coli , enteropathogenic Escherichia coli , enteroaggregative Escherichia coli , or carcinogenic Escherichia coli.

5. The composition of claim 1 , wherein the infection or disease is food poisoning, gastroenteritis, diarrhea, urinary tract infections, neonatal meningitis, hemolytic-uremic syndrome, peritonitis, mastitis, septicemia, Gram-negative pneumonia, shigellosis, dysentery, or cancer.

6. The composition of claim 1 , wherein the composition is a solution, suspension, emulsion in oil, water-soluble medium, extract, powder, granule, tablet, or capsule.

7. The composition of claim 1 further comprising:
a second bacteriophage having an ability to lyse a pathogenic Escherichia coli or a non- Escherichia coli bacterial species.

Assignees

• Intron Biotechnology Inc

Inventors

• Yoon Seong Jun
• Son Jee Soo
• Kim In Hwang
• Paik Hyoung Rok
• Im Hyun Joo
• Park Ji Young
• Yu Hyun Jin
• Seo Ji Yeong
• Jun Soo Youn
• Kang Sang Hyeon

Classifications

• A61P31/04 Primary

  Antibacterial agents · CPC title

• C12N2795/10132

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K35/76 Primary

  Viruses; Subviral particles; Bacteriophages · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title